Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
29 11 2021
29 11 2021
Historique:
received:
15
02
2021
accepted:
09
11
2021
revised:
01
11
2021
entrez:
30
11
2021
pubmed:
1
12
2021
medline:
26
3
2022
Statut:
epublish
Résumé
Breast cancer (BC) is the most common cancer occurring in women but also rarely develops in men. Recent advances in early diagnosis and development of targeted therapies have greatly improved the survival rate of BC patients. However, the basal-like BC subtype (BLBC), largely overlapping with the triple-negative BC subtype (TNBC), lacks such drug targets and conventional cytotoxic chemotherapies often remain the only treatment option. Thus, the development of resistance to cytotoxic therapies has fatal consequences. To assess the involvement of epigenetic mechanisms and their therapeutic potential increasing cytotoxic drug efficiency, we combined high-throughput RNA- and ChIP-sequencing analyses in BLBC cells. Tumor cells surviving chemotherapy upregulated transcriptional programs of epithelial-to-mesenchymal transition (EMT) and stemness. To our surprise, the same cells showed a pronounced reduction of polycomb repressive complex 2 (PRC2) activity via downregulation of its subunits Ezh2, Suz12, Rbbp7 and Mtf2. Mechanistically, loss of PRC2 activity leads to the de-repression of a set of genes through an epigenetic switch from repressive H3K27me3 to activating H3K27ac mark at regulatory regions. We identified Nfatc1 as an upregulated gene upon loss of PRC2 activity and directly implicated in the transcriptional changes happening upon survival to chemotherapy. Blocking NFATc1 activation reduced epithelial-to-mesenchymal transition, aggressiveness, and therapy resistance of BLBC cells. Our data demonstrate a previously unknown function of PRC2 maintaining low Nfatc1 expression levels and thereby repressing aggressiveness and therapy resistance in BLBC.
Identifiants
pubmed: 34845197
doi: 10.1038/s41419-021-04407-y
pii: 10.1038/s41419-021-04407-y
pmc: PMC8630036
doi:
Substances chimiques
Polycomb Repressive Complex 2
EC 2.1.1.43
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1118Informations de copyright
© 2021. The Author(s).
Références
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. [Internet]. https://gco.iarc.fr/today . Accessed 29 Sept 2021.
Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, et al. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat. 2019;173:37–48.
pubmed: 30267249
doi: 10.1007/s10549-018-4921-9
Harbeck N, Gnant M. Breast cancer. Lancet 2017;389:1134–50.
pubmed: 27865536
doi: 10.1016/S0140-6736(16)31891-8
Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–32.
pubmed: 12393819
doi: 10.1056/NEJMoa020989
Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41. 17
pubmed: 12393820
doi: 10.1056/NEJMoa022152
Colzani E, Johansson ALVV, Liljegren A, Foukakis T, Clements M, Adolfsson J, et al. Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics. Br J Cancer. 2014;110:1378–84. 4
pubmed: 24434426
pmcid: 3950882
doi: 10.1038/bjc.2014.5
Mathiesen RR, Fjelldal R, Liestøl K, Due EU, Geigl JB, Riethdorf S, et al. High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer. Int J Cancer. 2012;131:E405–15. 15
pubmed: 21935921
doi: 10.1002/ijc.26444
Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 2015;24:S26–35.
pubmed: 26253814
doi: 10.1016/j.breast.2015.07.008
Perou CM, Sørile T, Eisen MB, Van De Rijn M, Jeffrey SS, Ress CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747–52.
pubmed: 10963602
doi: 10.1038/35021093
Prat A, Fan C, Fernández A, Hoadley KA, Martinello R, Vidal M, et al. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Med. 2015;13:1–11.
doi: 10.1186/s12916-015-0540-z
Lu W, Kang Y. Epithelial–mesenchymal plasticity in cancer progression and metastasis. Dev Cell. 2019;49:361–74.
pubmed: 31063755
pmcid: 6506183
doi: 10.1016/j.devcel.2019.04.010
Ye X, Weinberg RA. Epithelial–mesenchymal plasticity: a central regulator of cancer progression. vol. 25, Trends in cell biology. Elsevier Ltd; 2015. p. 675–86.
Mohammad HP, Barbash O, Creasy CL. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nat Med. 2019;25:403–18.
pubmed: 30842676
doi: 10.1038/s41591-019-0376-8
Wainwright EN, Scaffidi P. Epigenetics and cancer stem cells: unleashing, hijacking, and restricting cellular plasticity. Trends Cancer. 2017;3:372–386.
pubmed: 28718414
pmcid: 5506260
doi: 10.1016/j.trecan.2017.04.004
Skrypek N, Goossens S, De Smedt E, Vandamme N, Berx G. Epithelial-to-mesenchymal transition: epigenetic reprogramming driving cellular plasticity. Trends Genet. 2017;33:943–59.
pubmed: 28919019
doi: 10.1016/j.tig.2017.08.004
Antonysamy S, Condon B, Druzina Z, Bonanno JB, Gheyi T, Zhang F, et al. Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-Ray crystallographic analysis of the EZH2-SET domain. PLoS ONE. 2013;8:1–15.
doi: 10.1371/journal.pone.0084147
Simon JA, Kingston RE. Occupying chromatin: polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. Mol Cell. 2013;49:808–24.
Vizán P, Beringer M, Ballaré C, Di Croce L. Role of PRC2-associated factors in stem cells and disease. FEBS J. 2015;282:1723–35.
pubmed: 25271128
doi: 10.1111/febs.13083
Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011;469:343–9.
pubmed: 21248841
pmcid: 3760771
doi: 10.1038/nature09784
Wen Y, Cai J, Hou Y, Huang Z, Wang Z. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target. Oncotarget 2017;8:37974–90.
pubmed: 28415635
pmcid: 5514966
doi: 10.18632/oncotarget.16467
Herranz N, Pasini D, Díaz VM, Francí C, Gutierrez A, Dave N, et al. Polycomb complex 2 Is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol. 2008;28:4772–81.
pubmed: 18519590
pmcid: 2493371
doi: 10.1128/MCB.00323-08
Martínez-Fernández M, Dueñas M, Feber A, Segovia C, García-Escudero R, Rubio C, et al. A Polycomb-mir200 loop regulates clinical outcome in bladder cancer. Oncotarget 2015;6:42258–75.
pubmed: 26517683
pmcid: 4747223
doi: 10.18632/oncotarget.5546
Schulze-Garg C, Löhler J, Gocht A, Deppert W. A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland. Oncogene 2000;19:1028–37.
pubmed: 10713686
doi: 10.1038/sj.onc.1203281
Maenz C, Lenfert E, Pantel K, Schumacher U, Deppert W, Wegwitz F. Epithelial-mesenchymal plasticity is a decisive feature for the metastatic outgrowth of disseminated WAP-T mouse mammary carcinoma cells. BMC Cancer. 2015;15:1–10.
doi: 10.1186/s12885-015-1165-5
Otto B, Gruner K, Heinlein C, Wegwitz F, Nollau P, Ylstra B, et al. Low-grade and high-grade mammary carcinomas in WAP-T transgenic mice are independent entities distinguished by Met expression. Int J Cancer. 2013;132:1300–10.
pubmed: 22907219
doi: 10.1002/ijc.27783
Lenfert E, Maenz C, Heinlein C, Jannasch K, Schumacher U, Pantel K, et al. Mutant p53 promotes epithelial–mesenchymal plasticity and enhances metastasis in mammary carcinomas of WAP-T mice. Int J Cancer. 2015;136:E521–33.
pubmed: 25195563
doi: 10.1002/ijc.29186
Wegwitz F, Lenfert E, Gerstel D, von Ehrenstein L, Einhoff J, Schmidt G, et al. CEACAM1 controls the EMT switch in murine mammary carcinoma in vitro and in vivo. Oncotarget 2016;7:63730–46.
pubmed: 27572314
doi: 10.18632/oncotarget.11650
Gerstel D, Wegwitz F, Jannasch K, Ludewig P, Scheike K, Alves F, et al. CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. Oncogene 2011;30:4275–88.
pubmed: 21532628
doi: 10.1038/onc.2011.146
Wegwitz F, Kluth M-AA, Mänz C, Otto B, Gruner K, Heinlein C, et al. Tumorigenic WAP-T mouse mammary carcinoma cells: a model for a self-reproducing homeostatic cancer cell system. Najbauer J, editor. PLoS ONE 2010;5:e12103.
Quante T, Wegwitz F, Abe J, Rossi A, Deppert W, Bohn W. Aberrant proliferation of differentiating alveolar cells induces hyperplasia in resting mammary glands of SV40-TAg transgenic mice. Front Oncol. 2014;4:168.
Jannasch K, Wegwitz F, Lenfert E, Maenz C, Deppert W, Alves F. Chemotherapy of WAP-T mouse mammary carcinomas aggravates tumor phenotype and enhances tumor cell dissemination. Int J Cancer. 2015;137:25–36.
pubmed: 25449528
doi: 10.1002/ijc.29369
Kiesslich T, Pichler M, Neureiter D. Epigenetic control of epithelial–mesenchymal-transition in human cancer. Mol Clin Oncol. 2012;1:3–11.
pubmed: 24649114
pmcid: 3956244
doi: 10.3892/mco.2012.28
Cardenas H, Zhao J, Vieth E, Nephew KP, Matei D. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells. Oncotarget 2016;7:84453–67.
pubmed: 27563817
pmcid: 5356672
doi: 10.18632/oncotarget.11497
Song X, Gao T, Wang N, Feng Q, You X, Ye T, et al. Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer. Sci Rep. 2016;6:20864.
pubmed: 26868841
pmcid: 4751454
doi: 10.1038/srep20864
Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M, et al. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 2009;28:843–53.
pubmed: 19079346
doi: 10.1038/onc.2008.433
Chen NM, Neesse A, Dyck ML, Steuber B, Koenig AO, Lubeseder-Martellato C, et al. Context-dependent epigenetic regulation of nuclear factor of activated T cells 1 in pancreatic plasticity. Gastroenterology 2017;152:1507–1520.e15.
pubmed: 28188746
doi: 10.1053/j.gastro.2017.01.043
Flores C, Fouquet G, Moura IC, Maciel TT, Hermine O. Lessons to learn from low-dose cyclosporin-A: a new approach for unexpected clinical applications. Front Immunol. 2019;10:588.
pubmed: 30984176
pmcid: 6447662
doi: 10.3389/fimmu.2019.00588
Sengupta S, Jana S, Biswas S, Mandal PK, Bhattacharyya A. Cooperative involvement of NFAT and SnoN mediates transforming growth factor-β (TGF-β) induced EMT in metastatic breast cancer (MDA-MB 231) cells. Clin Exp Metastasis. 2013;30:1019–31.
pubmed: 23832742
doi: 10.1007/s10585-013-9600-y
Singh SK, Chen N, Hessmann E, Siveke J, Lahmann M, Singh G, et al. Antithetical NFAT c1–Sox2 and p53–miR200 signaling networks govern pancreatic cancer cell plasticity. EMBO J. 2015;34:517–30.
pubmed: 25586376
pmcid: 4331005
doi: 10.15252/embj.201489574
Steinbichler TB, Dudás J, Skvortsov S, Ganswindt U, Riechelmann H, Skvortsova II. Therapy resistance mediated by cancer stem cells. Semin Cancer Biol. 2018;53:156–67.
pubmed: 30471331
doi: 10.1016/j.semcancer.2018.11.006
Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 2009;106:13820–5.
pubmed: 19666588
pmcid: 2720409
doi: 10.1073/pnas.0905718106
Scheel C, Weinberg RA. Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer. 2011;129:2310–4.
pubmed: 21792896
pmcid: 3357895
doi: 10.1002/ijc.26311
Kalluri R, Weinberg RA. The basics of epithelial–mesenchymal transition. J Clin Investig 2009;119:1420–8.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704–15.
pubmed: 18485877
pmcid: 2728032
doi: 10.1016/j.cell.2008.03.027
Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69:4116–24.
pubmed: 19435916
pmcid: 2737191
doi: 10.1158/0008-5472.CAN-08-3441
Loret N, Denys H, Tummers P, Berx G. The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance. Cancers. 2019;11:1–22.
doi: 10.3390/cancers11060838
Gooding AJ, Schiemann WP. Epithelial–mesenchymal transition programs and cancer stem cell phenotypes: mediators of breast cancer therapy resistance. Mol Cancer Res. 2020;18:1257–70.
pubmed: 32503922
pmcid: 7483945
doi: 10.1158/1541-7786.MCR-20-0067
Guo L, Lee YT, Zhou Y, Huang Y. Targeting epigenetic regulatory machinery to overcome cancer therapy resistance. Semin Cancer Biol. 2021:S1044-579X(20)30282-0.
Deblois G, Madani Tonekaboni SA, Grillo G, Martinez C, Kao YI, Tai F, et al. Epigenetic switch-induced viral mimicry evasion in chemotherapy resistant breast cancer. Cancer Discov. 2020;10:1312–1329.
Yomtoubian S, Lee SB, Verma A, Izzo F, Markowitz G, Choi H, et al. Inhibition of EZH2 catalytic activity selectively targets a metastatic subpopulation in triple-negative breast cancer. Cell Rep. 2020;30:755–770.e6.
pubmed: 31968251
doi: 10.1016/j.celrep.2019.12.056
Zhang Y, Liu G, Lin C, Liao G, Tang B. Silencing the EZH2 gene by RNA interference reverses the drug resistance of human hepatic multidrug-resistant cancer cells to 5-Fu. Life Sci. 2013;92:896–902.
pubmed: 23562851
doi: 10.1016/j.lfs.2013.03.010
Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J, et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther. 2010;10:788–95.
pubmed: 20686362
doi: 10.4161/cbt.10.8.12913
Chien Y-C, Liu L-C, Ye H-Y, Wu J-Y, Yu Y-L. EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway. Am J Cancer Res. 2018;8:422–34.
pubmed: 29636998
pmcid: 5883093
Huang JP, Ling K. EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys27 acetylation in the BIM gene promoter and enhancers. Oncol Lett. 2017;14:5735–42.
pubmed: 29113202
pmcid: 5661363
Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris M, Hsu C-C, et al. EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming. Cancer Res. 2017;77:6651–66.
pubmed: 28978636
pmcid: 5712262
doi: 10.1158/0008-5472.CAN-17-0899
Li Z, Hou P, Fan D, Dong M, Ma M, Li H, et al. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer. Cell Death Differ. 2017;24:59–71.
pubmed: 27716745
doi: 10.1038/cdd.2016.95
Hirukawa A, Smith HW, Zuo D, Dufour CR, Savage P, Bertos N, et al. Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program. Nat Commun. 2018;9:2547.
pubmed: 29959321
pmcid: 6026192
doi: 10.1038/s41467-018-04864-8
Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, et al. TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clin Cancer Res. 2017;23:7072–83.
pubmed: 28899973
pmcid: 5690819
doi: 10.1158/1078-0432.CCR-17-0413
Kikuchi J, Koyama D, Wada T, Izumi T, Hofgaard PO, Bogen B, et al. Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. J Clin Investig. 2015;125:4375–90.
pubmed: 26517694
pmcid: 4665777
doi: 10.1172/JCI80325
Ning X, Shi Z, Liu X, Zhang A, Han L, Jiang K, et al. DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression. Cancer Lett. 2015;359:198–205.
pubmed: 25595591
doi: 10.1016/j.canlet.2015.01.005
Vo BHT, Li C, Morgan MA, Theurillat I, Finkelstein D, Wright S, et al. Inactivation of Ezh2 upregulates Gfi1 and drives aggressive Myc-driven Group 3 medulloblastoma. Cell Rep. 2017;18:2907–17.
pubmed: 28329683
pmcid: 5415387
doi: 10.1016/j.celrep.2017.02.073
Wassef M, Rodilla V, Teissandier A, Zeitouni B, Gruel N, Sadacca B, et al. Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis. Genes Dev. 2015;29:2547–62.
pubmed: 26637281
pmcid: 4699384
doi: 10.1101/gad.269522.115
Sashida G, Wang C, Tomioka T, Oshima M, Aoyama K, Kanai A, et al. The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition. J Exp Med. 2016;213:1459–77.
pubmed: 27401345
pmcid: 4986523
doi: 10.1084/jem.20151121
Serresi M, Siteur B, Hulsman D, Company C, Schmitt MJ, Lieftink C, et al. Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities. J Exp Med. 2018;215:3115–35.
pubmed: 30487290
pmcid: 6279402
doi: 10.1084/jem.20180801
Serresi M, Gargiulo G, Proost N, Siteur B, Cesaroni M, Koppens M, et al. Polycomb repressive complex 2 is a barrier to KRAS-driven inflammation and epithelial–mesenchymal transition in non-small-cell lung cancer. Cancer Cell. 2016;29:17–31.
pubmed: 26766588
doi: 10.1016/j.ccell.2015.12.006
Wang Y, Hou N, Cheng X, Zhang J, Tan X, Zhang C, et al. Ezh2 acts as a tumor suppressor in kras-driven lung adenocarcinoma. Int J Biol Sci. 2017;13:652–9.
pubmed: 28539837
pmcid: 5441181
doi: 10.7150/ijbs.19108
Ariës IM, Bodaar K, Karim SA, Chonghaile TN, Hinze L, Burns MA, et al. PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med. 2018;215:3094–3114.
Göllner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, et al. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nat Med. 2017;23:69–78.
pubmed: 27941792
doi: 10.1038/nm.4247
Quan C, Chen Y, Wang X, Yang D, Wang Q, Huang Y, et al. Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Lett. 2020;495:41–52.
pubmed: 32920200
doi: 10.1016/j.canlet.2020.09.003
Wang Q, Chen X, Jiang Y, Liu S, Liu H, Sun X, et al. Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin. J Mol Cell Biol. 2020;12:125–137.
Liu F, Zhu Z, Mao Y, Liu M, Tang T, Qiu S. Inhibition of titanium particle-induced osteoclastogenesis through inactivation of NFATc1 by VIVIT peptide. Biomaterials 2009;30:1756–62.
pubmed: 19118894
doi: 10.1016/j.biomaterials.2008.12.018
Aramburu J, Yaffe MB, López-Rodríguez C, Cantley LC, Hogan PG, Rao A. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science (80-). 1999;285:2129–33.
doi: 10.1126/science.285.5436.2129
Tran Quang C, Leboucher S, Passaro D, Fuhrmann L, Nourieh M, Vincent-Salomon A, et al. The calcineurin/NFAT pathway is activated in diagnostic breast cancer cases and is essential to survival and metastasis of mammary cancer cells. Cell Death Dis. 2015;6:e1658–10.
pubmed: 25719243
pmcid: 4669815
doi: 10.1038/cddis.2015.14
Im JY, Lee KW, Won KJ, Kim BK, Ban HS, Yoon SH, et al. DNA damage-induced apoptosis suppressor (DDIAS), a novel target of NFATc1, is associated with cisplatin resistance in lung cancer. Biochim Biophys Acta - Mol Cell Res. 2016;1863:40–9.
doi: 10.1016/j.bbamcr.2015.10.011
Metzelder SK, Michel C, von Bonin M, Rehberger M, Hessmann E, Inselmann S, et al. NFATc1 as a therapeutic target in FLT3-ITD-positive AML. Leukemia 2015;29:1470–7.
pubmed: 25976987
doi: 10.1038/leu.2015.95
Kawahara T, Kashiwagi E, Ide H, Li Y, Zheng Y, Miyamoto Y, et al. Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1. Oncotarget 2015;6:1582–93.
pubmed: 25638160
pmcid: 4359316
doi: 10.18632/oncotarget.2750
Klein-Hessling S, Muhammad K, Klein M, Pusch T, Rudolf R, Flöter J, et al. NFATc1 controls the cytotoxicity of CD8+ T cells. Nat Commun. 2017;8:511.
Prokakis E, Dyas A, Grün R, Fritzsche S, Bedi U, Kazerouni ZB, et al. USP22 promotes HER2-driven mammary carcinoma aggressiveness by suppressing the unfolded protein response. Oncogene 2021;40:4004–18.
pubmed: 34007022
pmcid: 8195738
doi: 10.1038/s41388-021-01814-5
Hamdan FH, Johnsen SA. DeltaNp63-dependent super enhancers define molecular identity in pancreatic cancer by an interconnected transcription factor network. Proc Natl Acad Sci USA. 2018;115:E12343–52.
pubmed: 30541891
pmcid: 6310858
doi: 10.1073/pnas.1812915116
Wegwitz F, Prokakis E, Pejkovska A, Kosinsky RL, Glatzel M, Pantel K, et al. The histone H2B ubiquitin ligase RNF40 is required for HER2-driven mammary tumorigenesis. Cell Death Dis. 2020;11:873.
Wilting J, Christ B, Bokeloh M. A modified chorioallantoic membrane (CAM) assay for qualitative and quantitative study of growth factors—studies on the effects of carriers, PBS, angiogenin, and bFGF. Anat Embryol. 1991;183:259–71.
doi: 10.1007/BF00192214